Most people whose brains exhibit Alzheimer's pathology don’t have the disease; they reach the end of their lives never having exhibited cognitive impairment. A new study examines the genetics of this resilience.

A new study will use innovative methods developed at VUMC to look for drugs already approved for other uses that could potentially be repurposed to treat Alzheimer's.

By 2017, on the back of the opioid crisis, the rate of neonatal opioid withdrawal syndrome in the U.S. was estimated to have reached 7.3 per 1000 deliveries. Meanwhile, many newborns exposed to opioids in utero never develop the syndrome and must undergo needless monitoring in the hospital after birth.

An observational study found that bariatric surgery was associated with 63% reduced risk of Alzheimer's disease and related dementias.

Through a new tool offered by ResearchMatch, researchers planning trials can quickly survey potential participants about topics ranging from participant compensation to protocol design.

The 12 authors of the recommendations are mainly academics but also include leaders from tech companies Microsoft, Google and Epic.